Cardiovascular pharmacotherapy in patients with marfan syndrome

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The cardiovascular complications of Marfan syndrome (MFS) remain the primary source of morbidity and mortality in affected patients. Over the last decade, the underlying pathogenesis of these cardiovascular abnormalities has been the focus of much research. Such research has shed light on the potential role of several novel medical therapies and their ability to prevent cardiovascular disease progression. This paper summarizes the research underlying new medical therapies and provides a review of the scientific foundation underlying all current medical therapies used for prevention of cardiovascular disease in patients with MFS, including β-adrenoceptor antagonists, calcium channel antagonists, ACE inhibitors, and angiotensin receptor antagonists.

Original languageEnglish (US)
Pages (from-to)117-126
Number of pages10
JournalAmerican Journal of Cardiovascular Drugs
Volume7
Issue number2
DOIs
StatePublished - May 28 2007

Fingerprint

Marfan Syndrome
Drug Therapy
Cardiovascular Diseases
Research
Cardiovascular Abnormalities
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Adrenergic Receptors
Disease Progression
Therapeutics
Morbidity
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Cardiovascular pharmacotherapy in patients with marfan syndrome. / Yetman, Anji T.

In: American Journal of Cardiovascular Drugs, Vol. 7, No. 2, 28.05.2007, p. 117-126.

Research output: Contribution to journalReview article

@article{c4791d4bfe28481b849dd193cb199059,
title = "Cardiovascular pharmacotherapy in patients with marfan syndrome",
abstract = "The cardiovascular complications of Marfan syndrome (MFS) remain the primary source of morbidity and mortality in affected patients. Over the last decade, the underlying pathogenesis of these cardiovascular abnormalities has been the focus of much research. Such research has shed light on the potential role of several novel medical therapies and their ability to prevent cardiovascular disease progression. This paper summarizes the research underlying new medical therapies and provides a review of the scientific foundation underlying all current medical therapies used for prevention of cardiovascular disease in patients with MFS, including β-adrenoceptor antagonists, calcium channel antagonists, ACE inhibitors, and angiotensin receptor antagonists.",
author = "Yetman, {Anji T.}",
year = "2007",
month = "5",
day = "28",
doi = "10.2165/00129784-200707020-00003",
language = "English (US)",
volume = "7",
pages = "117--126",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Cardiovascular pharmacotherapy in patients with marfan syndrome

AU - Yetman, Anji T.

PY - 2007/5/28

Y1 - 2007/5/28

N2 - The cardiovascular complications of Marfan syndrome (MFS) remain the primary source of morbidity and mortality in affected patients. Over the last decade, the underlying pathogenesis of these cardiovascular abnormalities has been the focus of much research. Such research has shed light on the potential role of several novel medical therapies and their ability to prevent cardiovascular disease progression. This paper summarizes the research underlying new medical therapies and provides a review of the scientific foundation underlying all current medical therapies used for prevention of cardiovascular disease in patients with MFS, including β-adrenoceptor antagonists, calcium channel antagonists, ACE inhibitors, and angiotensin receptor antagonists.

AB - The cardiovascular complications of Marfan syndrome (MFS) remain the primary source of morbidity and mortality in affected patients. Over the last decade, the underlying pathogenesis of these cardiovascular abnormalities has been the focus of much research. Such research has shed light on the potential role of several novel medical therapies and their ability to prevent cardiovascular disease progression. This paper summarizes the research underlying new medical therapies and provides a review of the scientific foundation underlying all current medical therapies used for prevention of cardiovascular disease in patients with MFS, including β-adrenoceptor antagonists, calcium channel antagonists, ACE inhibitors, and angiotensin receptor antagonists.

UR - http://www.scopus.com/inward/record.url?scp=34249025728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249025728&partnerID=8YFLogxK

U2 - 10.2165/00129784-200707020-00003

DO - 10.2165/00129784-200707020-00003

M3 - Review article

C2 - 17503882

AN - SCOPUS:34249025728

VL - 7

SP - 117

EP - 126

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 2

ER -